|
1
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meyer M, Clauss M, Lepple-Wienhues A, et
al: A novel vascular endothelial growth factor encoded by Orf
virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2
(KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J.
18:363–374. 1999. View Article : Google Scholar
|
|
5
|
Yamazaki Y and Morita T: Molecular and
functional diversity of vascular endothelial growth factors. Mol
Divers. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamazaki Y, Takani K, Atoda H and Morita
T: Snake venom vascular endothelial growth factors (VEGFs) exhibit
potent activity through their specific recognition of KDR (VEGF
receptor 2). J Biol Chem. 278:51985–51988. 2003. View Article : Google Scholar
|
|
7
|
Plate KH, Breier G, Weich HA and Risau W:
Vascular endothelial growth factor is a potential tumour
angiogenesis factor in human gliomas in vivo. Nature. 359:845–848.
1992. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shweiki D, Itin A, Soffer D and Keshet E:
Vascular endothelial growth factor induced by hypoxia may mediate
hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dameron KM, Volpert OV, Tainsky MA and
Bouck N: Control of angiogenesis in fibroblasts by p53 regulation
of thrombospondin-1. Science. 265:1582–1584. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kieser A, Weich HA, Brandner G, Marme D
and Kolch W: Mutant p53 potentiates protein kinase C induction of
vascular endothelial growth factor expression. Oncogene. 9:963–969.
1994.PubMed/NCBI
|
|
11
|
Mukhopadhyay D, Tsiokas L and Sukhatme VP:
Wild-type p53 and v-Src exert opposing influences on human vascular
endothelial growth factor gene expression. Cancer Res.
55:6161–6165. 1995.PubMed/NCBI
|
|
12
|
Volpert OV, Dameron KM and Bouck N:
Sequential development of an angiogenic phenotype by human
fibroblasts progressing to tumorigenicity. Oncogene. 14:1495–1502.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harada H, Nakagawa K, Iwata S, et al:
Restoration of wild-type p16 down-regulates vascular endothelial
growth factor expression and inhibits angiogenesis in human
gliomas. Cancer Res. 59:3783–3789. 1999.PubMed/NCBI
|
|
14
|
Siemeister G, Weindel K, Mohrs K, Barleon
B, Martiny-Baron G and Marme D: Reversion of deregulated expression
of vascular endothelial growth factor in human renal carcinoma
cells by von Hippel-Lindau tumor suppressor protein. Cancer Res.
56:2299–2301. 1996.
|
|
15
|
Mukhopadhyay D, Knebelmann B, Cohen HT,
Ananth S and Sukhatme VP: The von Hippel-Lindau tumor suppressor
gene product interacts with Sp1 to repress vascular endothelial
growth factor promoter activity. Mol Cell Biol. 17:5629–5639.
1997.PubMed/NCBI
|
|
16
|
Inoue K, Slaton JW, Karashima T, et al:
The prognostic value of angiogenesis factor expression for
predicting recurrence and metastasis of bladder cancer after
neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res.
6:4866–4873. 2000.
|
|
17
|
Jacobsen J, Rasmuson T, Grankvist K and
Ljungberg B: Vascular endothelial growth factor as prognostic
factor in renal cell carcinoma. J Urol. 163:343–347. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisma RJ, Spiro JD and Kreutzer DL:
Vascular endothelial growth factor expression in head and neck
squamous cell carcinoma. Am J Surg. 174:513–517. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong MP, Cheung N, Yuen ST, Leung SY and
Chung LP: Vascular endothelial growth factor is up-regulated in the
early pre-malignant stage of colorectal tumour progression. Int J
Cancer. 81:845–850. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amaya H, Tanigawa N, Lu C, et al:
Association of vascular endothelial growth factor expression with
tumor angiogenesis, survival and thymidine
phosphorylase/platelet-derived endothelial cell growth factor
expression in human colorectal cancer. Cancer Lett. 119:227–235.
1997. View Article : Google Scholar
|
|
21
|
Guidi AJ, Abu-Jawdeh G, Berse B, et al:
Vascular permeability factor (vascular endothelial growth factor)
expression and angiogenesis in cervical neoplasia. J Natl Cancer
Inst. 87:1237–1245. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boocock CA, Charnock-Jones DS, Sharkey AM,
et al: Expression of vascular endothelial growth factor and its
receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst.
87:506–516. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O’Byrne KJ, Koukourakis MI, Giatromanolaki
A, et al: Vascular endothelial growth factor, platelet-derived
endothelial cell growth factor and angiogenesis in non-small-cell
lung cancer. Br J Cancer. 82:1427–1432. 2000.
|
|
24
|
Brown LF, Berse B, Jackman RW, et al:
Expression of vascular permeability factor (vascular endothelial
growth factor) and its receptors in breast cancer. Hum Pathol.
26:86–91. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshiji H, Gomez DE, Shibuya M and
Thorgeirsson UP: Expression of vascular endothelial growth factor,
its receptor, and other angiogenic factors in human breast cancer.
Cancer Res. 56:2013–2016. 1996.PubMed/NCBI
|
|
26
|
Kadrmas JL and Beckerle MC: The LIM
domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell
Biol. 5:920–931. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hubbi ME, Gilkes DM, Baek JH and Semenza
GL: Four-and-a-half LIM domain proteins inhibit transactivation by
hypoxia-inducible factor 1. J Biol Chem. 287:6139–6149. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin J, Qin X, Zhu Z, Mu J, et al: FHL
family members suppress vascular endothelial growth factor
expression through blockade of dimerization of HIF1α and HIF1β.
IUBMB Life. 64:921–930. 2012.PubMed/NCBI
|
|
29
|
Schwarte-Waldhoff I, Volpert OV, Bouck NP,
et al: Smad4/DPC4-mediated tumor suppression through suppression of
angiogenesis. Proc Natl Acad Sci USA. 97:9624–9629. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding L, Wang Z, Yan J, et al: Human
four-and-a-half LIM family members suppress tumor cell growth
through a TGF-beta-like signaling pathway. J Clin Invest.
119:349–361. 2009.PubMed/NCBI
|
|
31
|
Xiong Z, Ding L, Sun J, et al: Synergistic
repression of estrogen receptor transcriptional activity by FHL2
and Smad4 in breast cancer cells. IUBMB Life. 62:669–676. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin J, Ding L, Jin R, et al: Four and a
half LIM domains 1 (FHL1) and receptor interacting protein of
140kDa (RIP140) interact and cooperate in estrogen signaling. Int J
Biochem Cell Biol. 41:1613–1618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun Y, Ding L, Zhang H, et al:
Potentiation of Smad-mediated transcriptional activation by the
RNA-binding protein RBPMS. Nucleic Acids Res. 34:6314–6326. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding L, Yan J, Zhu J, et al:
Ligand-independent activation of estrogen receptor alpha by XBP-1.
Nucleic Acids Res. 31:5266–5274. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Matsumoto M, Kawakami K, Enokida H, et al:
CpG hypermethylation of human four-and-a-half LIM domains 1
contributes to migration and invasion activity of human bladder
cancer. Int J Mol Med. 26:241–247. 2010.
|
|
36
|
Papageorgis P, Cheng K, Ozturk S, et al:
Smad4 inactivation promotes malignancy and drug resistance of colon
cancer. Cancer Res. 71:998–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yatsuoka T, Sunamura M, Furukawa T, et al:
Association of poor prognosis with loss of 12q, 17p, and 18q, and
concordant loss of 6q/17p and 12q/18q in human pancreatic ductal
adenocarcinoma. Am J Gastroenterol. 95:2080–2085. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sánchez-Elsner T, Botella LM, Velasco B,
et al: Synergistic cooperation between hypoxia and transforming
growth factor-beta pathways on human vascular endothelial growth
factor gene expression. J Biol Chem. 276:38527–38535.
2001.PubMed/NCBI
|
